Nektar Therapeutics (NASDAQ:NKTR) closed its last session at $84. The stock traded within a range of $70.45 and $86.87. The company operates in the Healthcare sector with a market capitalization of 13.23 Million. Trading volume for Nektar Therapeutics was 8.58 Million in its previous trading session. Currently, Nektar Therapeutics (NASDAQ:NKTR) has an average volume of 2.63 Million.
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company’s wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Nektar Therapeutics (NASDAQ:NKTR) received a Buy rating from 1 analysts. 0 analysts gave its stock an Outperform rating. 1 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.
Nektar Therapeutics (NASDAQ:NKTR) touched its 1-Year High price of $99.02 on 02/02/18 and its 1-Year Low price of $12.50 on 03/02/17.
EPS & Financials
Nektar Therapeutics (NASDAQ:NKTR) reported its EPS in the last quarter as $0.37/Share beating the analyst estimate of $0.18/Share by a difference of $0.19. This showed a surprise of 105.6% in the last quarter earnings.
For the current quarter, 7 analysts are projecting a mean EPS of $-0.34/share. According to their observations and findings, the stock could provide a high EPS of $-0.26/share and a low EPS of $-0.43/share.
Analysts believe that the company has the potential to earn average revenue of $38.82 Million for the current quarter. According to their predictions high & low revenue estimates are 48.1 Million and 28.43 Million respectively.
By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with HIGH volatility. Nektar Therapeutics (NASDAQ:NKTR) has a 20-Day average volume of 3 Million. According to today’s trading volume Nektar Therapeutics is ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.
Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BULLISH signal. The 100-Day trend also shows a BULLISH trend as well.
The company currently has an insider ownership of 1.2 Percent and Institutional ownership of 93.3 Percent. The return on assets stands at -19.5%, Return on Equity currently is -190.7% and the Return on Investment value is -33.8%.
Nektar Therapeutics (NASDAQ:NKTR) gross margin percentage stands at 89% while its operating margin for the past trailing twelve month is -27.1 percent and its overall profit margin (ttm) is -42.1 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 7.23% with a 50-Day Simple Moving Average of 26.35 percent. As of today, the company has a SMA200 (200-day simple moving average) of 145.38 Percent. The Stock has YTD (year to date) performance of 40.66 percent.
The TTM operating margin for the company stands at -27.1%. The return on invested capital is at -33.8%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.
The company’s stock is currently moving with a +ve distance from the 200 day SMA of approximately 145.38%, and has a solid year to date (YTD) performance of 40.66% which means that the stock is constantly adding to its value from the previous fiscal year end price.